

**Betty Uyesugi, M.D.**

**Education**

|                                                                                                |              |
|------------------------------------------------------------------------------------------------|--------------|
| <b>Board Certified American Board of Physical Medicine &amp; Rehabilitation</b>                | 2012-present |
| <b>Musculoskeletal Pain Fellowship</b><br>Indiana University, department of PM&R               | 2010-2011    |
| <b>PM&amp;R Residency</b><br>Indiana University School of Medicine<br>Served as Chief Resident | 2007-2010    |
| <b>Internal Medicine Residency, Categorical Year</b><br>Indiana University School of Medicine  | 2006-2007    |
| <b>Medical School</b><br>Indiana University School of Medicine                                 | 2002-2006    |
| <b>Undergraduate Training</b><br>Hanover College<br>Bachelor of Arts, Chemistry                | 1998-2002    |

**Clinical Study Experience**

---

|                                            |                 |
|--------------------------------------------|-----------------|
| <b>Sponsor: University of Pennsylvania</b> | <b>Phase: 4</b> |
|--------------------------------------------|-----------------|

---

A Pragmatic Trial of Home Versus Office Based Narrow Band Ultraviolet B Phototherapy for the Treatment of Psoriasis / Light Treatment Effectiveness (LITE) Study  
**October 2020 – May 2023**

---

|                                              |                            |
|----------------------------------------------|----------------------------|
| <b>Sponsor: Target PharmaSolutions, Inc.</b> | <b>Observational Study</b> |
|----------------------------------------------|----------------------------|

---

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Immune-Mediated Inflammatory Skin Conditions  
**October 2020 – Ongoing**

---

|                                                        |                            |
|--------------------------------------------------------|----------------------------|
| <b>Sponsor: CorEvitas, LLC (formerly Corrona, LLC)</b> | <b>Observational Study</b> |
|--------------------------------------------------------|----------------------------|

---

Corrona Atopic Dermatitis Registry: A Study of Post Approval Drug Safety and Effectiveness  
**October 2020 - Ongoing**

---

|                                                 |                 |
|-------------------------------------------------|-----------------|
| <b>Sponsor: Regeneron Pharmaceuticals, Inc.</b> | <b>Phase: 3</b> |
|-------------------------------------------------|-----------------|

---

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Moderate-to-Severe Atopic Hand and Foot Dermatitis  
**April 2021 – February 2023**

---

|                                               |                 |
|-----------------------------------------------|-----------------|
| <b>Sponsor: Celgene International II Sàrl</b> | <b>Phase: 2</b> |
|-----------------------------------------------|-----------------|

---

A Phase 2, Multicenter, Global, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of Cendakimab (CC-93538) in Adult Subjects with Moderate to Severe Atopic Dermatitis

  
11/5/2025

**June 2021 – December 2022**

---

**Sponsor:** Dermtech Operation, Inc. **Observational Study**  
A Sample Collection Study to Assess the Prevalence of Gene Mutations Associated with  
Photoaging in Facial Skin from Adults: Establishing Population Norms  
**February 2022 – January 2024**

---

**Sponsor:** Moonlake Immunotherapeutics AG **Phase: 2**  
Phase 2, Randomized, Parallel-Group, Double-Blind, Placebo-Controlled Study of Sonelokimab  
in Patients with Active Moderate to Severe Hidradenitis Suppurativa  
**April 2022 – October 2023**

---

**Sponsor:** Alumis Inc. **Phase: 2**  
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of  
ESK-001 in Patients with Moderate to Severe Plaque Psoriasis  
**November 2022 – September 2023**

---

**Sponsor:** Alumis Inc. **Phase: 2**  
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ESK-001 in  
Patients with Plaque Psoriasis  
**May 2023 – Ongoing**

---

**Sponsor:** Alumis Inc. **Phase: 3**  
An Extension Study in Patients with Moderate to Severe Plaque Psoriasis to Evaluate the Long-  
term Safety, Efficacy, and Durability of Response to ESK-001 (ONWARD3)  
**December 2024 - Ongoing**

---

**Sponsor:** Ventyx Biosciences, Inc. **Phase: 2**  
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study  
to Evaluate the Efficacy and Safety of VTX958 in participants with Moderate to Severe Psoriasis  
**November 2022 – February 2024**

---

**Sponsor:** Gilead Sciences, Inc. **Phase: 2a**  
A Randomized, Blinded, Placebo-Controlled, Phase 2a, Proof-of-Concept Study to Evaluate  
Efficacy, Safety, and Tolerability of GS-5718 in Participants With Cutaneous Lupus  
Erythematosus (CLE)  
**February 2023 – August 2024**

---

**Sponsor:** DICE Therapeutics, Inc. **Phase: 2**  
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging  
Study to Evaluate the Efficacy and Safety of DC-806 in Participants with Moderate to Severe  
Plaque Psoriasis  
**May 2023 – March 2024**

---

**Sponsor:** Sanofi-Aventis **Phase: 2**

---

**Betty Uyesugi, M.D.**

A parallel-group treatment, Phase 2, double-blind, placebo-controlled study to evaluate the efficacy and safety of SAR444656 in adult participants with moderate to severe hidradenitis suppurativa

**September 2023 – Ongoing**

**Sponsor: Taro Pharmaceuticals**

**Phase: 2**

A multi-center, double-blind, randomized, placebo controlled, parallel-group study, comparing Ruxolitinib topical cream 1.5% (Taro Pharmaceuticals U.S.A., Inc.) to Opzelura (Ruxolitinib) cream and both active treatments to a placebo control in the treatment of mild-to-moderate atopic dermatitis

**October 2023 – Ongoing**

**Sponsor: Alumis**

**Phase: 3**

A Multicenter, Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis

**June 2024 – Ongoing**

**Sponsor: The National Psoriasis Foundation**

**Phase: NA**

Prevention of cardiovascular disease and mortality in patients with psoriasis or psoriatic arthritis: Translating guidelines of care to better outcomes for patients with psoriatic disease

**November 2023 – Ongoing**

**Sponsor: Moonlake Immunotherapeutics AG**

**Phase: 3**

A parallel-group treatment, phase 3, randomized, double-blind, 2 arm study to investigate the efficacy and safety of subcutaneous sonelokimab compared with placebo in male and female participants aged 18 years or over with active moderate to severe hidradenitis suppurativa

**March 2024 – Ongoing**

**Sponsor: Moonlake Immunotherapeutics AG**

**Phase: 3**

An open-label, single-arm study to evaluate the pharmacokinetics and safety of subcutaneous sonelokimab in adolescents aged  $\geq 12$  to  $\leq 17$  years at the time of study inclusion with active moderate to severe hidradenitis suppurativa

**December 2024 – Ongoing**

**Sponsor: Moonlake Immunotherapeutics AG**

**Phase: 3**

A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

**13JUN2025 - Ongoing**

**Sponsor: Sanofi**

**Phase: 3**

A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults

**15APR2025 – Ongoing**

**Sponsor: Lilly**

**Phase: 4**

A Study to Investigate the Efficacy of Lebrikizumab in Participants with Atopic Dermatitis with Limited Body Surface Area Involvement and High Itch Burden

**14JUN2025 – Ongoing**

**Physiatric Work History**

03/2012-10/2012      Indianapolis VA PM&R department, fee basis  
10/2012-02/2015      Indianapolis VA Compensation & Pension department, fee basis

**Publications & Presentations**

2017-2019      **“Muscular Dystrophy”** Lecture for 2<sup>nd</sup> year medical students at Marion University College of Osteopathic Medicine.  
2007      **“Headaches.”** Nursing and Therapy Conference. Richard A. Roudebush VA.  
2008      **“Botox for Headaches”** Grand Rounds, presented to Indiana University Physical Medicine & Rehabilitation Department.  
2008      **Spinal Cord Injury: Presentation of Interesting Cases.** Therapy Conference Lecture. Rehabilitation Hospital of Indiana.  
2009      **Traumatic Brain Injury: Presentation of Interesting Cases.** Therapy Conference Lecture. Rehabilitation Hospital of Indiana.  
2009      **“Painful Shoulders.”** Overview of Common Shoulder Problems. Anatomy Lecture Series. IU PM&R Residency.  
2009      **“‘Dr., I Hurt my Knee.’ Common Clinical Problems.”** Overview of Common Knee Pathology. Anatomy Lecture Series. IU PM&R Residency.  
2010      **Botulinum Toxin Type A in the Treatment of a Painful Keloid.** Betty Uyesugi, M.D., Benjamin Lippincott M.D., Shashank Dave, D.O. American Journal of Physical Medicine & Rehabilitation.  
2010      **“Spinal Cord Infarction Following Lumbosacral Transforaminal Injection: Review of Emerging Literature.”** Grand Rounds, presented to Indiana University Physical Medicine & Rehabilitation Department.  
2010      **“Post-Stroke Spasticity: An Update on Diagnosis and Treatment Research.”** Grand Rounds, National Stroke Association, presented at Rehabilitation Hospital of Indiana.  
2011      **“Anatomy of the Extensor Forearm, Elbow, & Hand: Board Relevant Highlights.”** Anatomy Lecture Series, Presented to IU PM&R Residents  
2011      **“Botox for Migraines: A Focus on the Recent FDA Approval.”** Grand Rounds, presented to Indiana University Physical Medicine & Rehabilitation Department.